Abivax (ABVX) Enterprise Value (2021 - 2026)
Abivax (ABVX) posted quarterly Enterprise Value of -$584.7 million for Q1 2026, down 400.34% year-over-year from $194.7 million in Q1 2025, and up 6.65% quarter-over-quarter from -$626.4 million in Q4 2025.
Abivax (ABVX) Enterprise Value (2021 - 2026) Analysis & Trends
Abivax's Enterprise Value history runs 6 years deep, the most recent figure standing at -$584.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 400.34% year-over-year to -$584.7 million; the TTM figure through Mar 2026 stood at -$584.7 million (down 400.34% YoY), while the FY2025 annual figure was -$626.4 million, down 286.26% from the prior year.
- Enterprise Value for Q1 2026 stood at -$584.7 million, up from -$626.4 million in the prior quarter.
- The five-year high for Enterprise Value was -$27.5 million in Q4 2022, with the low at -$700.1 million in Q3 2025.
- The 5-year median for Enterprise Value is -$253.2 million (2024), against an average of -$299.1 million.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value tumbled 921.83% in 2023, then jumped 69.17% in 2025.
- Abivax's Enterprise Value stood at -$27.5 million in 2022, then sank by 921.83% to -$281.0 million in 2023, then soared by 42.28% to -$162.2 million in 2024, then tumbled by 286.26% to -$626.4 million in 2025, then increased by 6.65% to -$584.7 million in 2026.
- Business Quant data shows ABVX's Enterprise Value at -$584.7 million in Q1 2026, -$626.4 million in Q4 2025, and -$700.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -584.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -584.73 Mn |
| Dec 31, 2025 | -626.37 Mn |
| Sep 30, 2025 | -700.12 Mn |
| Jun 30, 2025 | -78.06 Mn |
| Mar 31, 2025 | -116.87 Mn |
| Dec 31, 2024 | -162.16 Mn |
| Sep 30, 2024 | -198.17 Mn |
| Jun 30, 2024 | -253.18 Mn |
| Mar 31, 2024 | -262.47 Mn |
| Dec 31, 2023 | -280.96 Mn |
| Dec 31, 2022 | -27.50 Mn |
| Dec 31, 2021 | -69.44 Mn |